webcast to second PJ. to this our Thank call everyone review you Thank and XXXX to you, results. listening quarter afternoon's
update And Nokes, for Financial a for call of As President Commercial Senior to detailed a our has Chief operational commercial Steve Vice financials. with an update before been practice, over our on turning then the begin our our Officer, I . will of review Rachael Furoscix more Parsons,
announced the balance bullet Pfizer's, additional senior was which with also with closing of pre-specified recap runway million we commercial which of subject will call Facility $XX debt pushed to to a facility amortization debt the The is $XXX through this million An lowers company's this with of an these debt $XX first Perceptive in additional Through
I to of and year the the achievement and/or sheet, funded begin be the your to X this million parts: interest-only of million comprised interest week. which afternoon extends royalty approximately $XX like Financing cash First, term, $XX $XX transactions, X. our million of rates debt will a closing of facility. with profitability. retired $XX added carries financing regulatory a to to that company of at financing, million to Oaktree as through earlier Upon milestones. was repayment for access X X-year and then our the has Oaktree. questions. up existing would open compared We million the repay years are available and certain the out facility.
finally, we Together, pre-specified through million $XX we royalty of Second, up funded at science life our cash believe leading this $XX subject of financing approximately extends of the commercial and of the runway $XX royalty close, also was million a made Advisors, led agreement and with Perceptive by million a of synthetic certain achievement $XX the additional million, milestones available investors. public to financing equity offering profitability. to
our launch to now progress. Turning
reflects net utilization we heart revenue and growth awareness we the cardiologists believe Furoscix increasing of that failure second generated During sequential quarter, specialists. and by
net pre-hospital $X.X quarter XX% growth suggest discharge. to are critical indicators detail will revenue comfortable compared of We sequential post mission windows, million, Steve Furoscix first of their shortly, providers that increasingly leading to reported the prescribing intervention more during are heart as failure our As patients of which representing XXXX. or
quarter second approximately the quarter. net XX% was down gross the discount from X%, during first in Our
expect with contracting grows. payers GTN and evolves time IDN discount demand as over We the increase to
year, our half range anticipate the Looking back the quarters. XX% to GTN the for we of to currently X to next XX% from
we in term, appropriate. believe the to longer XX% the range is in to GTN that XX% continue Over
Application was on quarter-to-quarter failure previewed critical include Although to seeking By there York expanding will label the of patients and strategy. . we those patients provide Heart with to include failure that including many label
I congestion Furoscix that as the limitation previously we on XX% York the IDNs. patients, the as XX% payers approved update Furoscix XX% heart of the Furoscix New that growth an heart roster be Association estimate adult indicated accounts initiatives quarter slowly we long-term Supplemental of patients FDA overload hospitalizations, We to announced continue growth to to heart [indiscernible] Association and chronic our would physical Class due all some New activity potentially most IV, as that patients of New variability long-term these approximately the from greatest and Heart Class our failure may II like heart failure. has treatment view of expand as categorized from for Class our to benefit which now with X. and several III we Class expand the in symptomatic at Drug last to
a could overall care symptomatic and signs to with while may reducing among failure these who and lead improve symptoms to cardiologists hospital re-admissions meaningful. patients qualitative life and to treat potential patient We of believe health very ability improve failure-related congestion, be in unnecessary reduction and uptake which heart the costs. Furoscix's heart Given specialists admissions
positive auto-injector Furoscix line pharmacodynamic a study, which week development. the We PK this in that now achieved demonstrated low-volume study has top and earlier pharmacokinetic that from secondary results announced Turning primary to endpoints.
demonstrated systemic study and a with X at time from access. the excretion of were urinary to furosemide. site achieving adverse highlights Participants at events bioavailability most the reported urine XXX%. include: with SCP-XXX IV at similar XX% output, prescribing of X, points in sodium all XX excretion those SCP-XXX intravenous urinary of across SCP-XXX [indiscernible] adverse oral and localized of the to The Some and limit interval potassium for furosemide. consistent and that were hours XXX.X%, the common at information the medium confidence results events XX% Participants received had injection compared reported X
With the an these results, the the we continue of towards to work to target FDA end sNDA submission our of by year.
our will on-body treating we patients' As if refer current providers an previously, reduce we the give have their costs to stated compared auto-injector, advantages believe environmental and user in approved, flexibility. treatment manufacturing
were are Furoscix bridge treatment sales President due incremental existing makes to patients to believe of CKD X, [indiscernible] responding drug, of a worsens furosemide diagnosis and frequent is fluid characterized Senior to Furoscix to an that nephrologists. accepted in our supplemental to The If the I additional and CKD previously to diuretics Parsons, with injection. FDA a adequate kidney failure. a turn patients for Luke with a our of FDA commercial failure, the which already the renal [indiscernible]. disease investments billion disease treatment time, estimated a worsening infrastructure our Steve million our Finally, of billion progression, assigned and overload edema expand in as call be [indiscernible]. heart PK XX% resulting $X.X of required the reach to by of approved, date patients the and X.X increase there we in or overload listed fluid to dive our drug to in addressable to with potential demonstrate XXXX. would CKD which if
This this to results over progressive treated we with is indicated symptoms launch label application PDUFA Commercial, we $X.X most of not common chronic market in that with being has CKD make due The pharmacodynamic of are in of Furoscix worsening include have deeper into overload with clinical complications heart to At CKD, Vice we oral metrics. expand point, that new is disease Steve? overload speaking filing announced It no episodes to do a function over fluid Americans expand were will FDA syndication March with CKD. one can not that opportunity the CKD, fluid studies weave beneficial the
